Verteporfin protects against Th17 cell-mediated EAE independently of YAP inhibition

Paulin Brosinsky; Hanna Leister; Nan Cheng; Xaralabos Varelas; Alexander Visekruna; Maik Luu

doi:10.1002/eji.202149564

Verteporfin protects against Th17 cell-mediated EAE independently of YAP inhibition

Eur J Immunol. 2022 Sep;52(9):1523-1526. doi: 10.1002/eji.202149564. Epub 2022 Jul 25.

Authors

Paulin Brosinsky¹, Hanna Leister¹, Nan Cheng², Xaralabos Varelas², Alexander Visekruna¹, Maik Luu^{1

3}

Affiliations

¹ Institute for Medical Microbiology and Hygiene, Philipps-University Marburg, Marburg, Germany.
² Department of Biochemistry, Boston University School of Medicine, Massachusetts, United States of America.
³ Lehrstuhl für Zelluläre Immuntherapie, Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.

PMID: 35776890
DOI: 10.1002/eji.202149564

Abstract

The known YAP inhibitor verteporfin is capable of repressing IL-17A production in Th17 cells. However, this effect is mediated independently of YAP and can ameliorate Th17-mediated experimental autoimmune encephalomyelitis (EAE) upon in vivo administration. The data suggest verteprofin's mode of action for the design of novel therapeutic autoimmune disease intervention.

Keywords: EAE; Hippo signaling; Th17 cells; YAP; verteporfin.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Encephalomyelitis, Autoimmune, Experimental* / drug therapy
Mice
Mice, Inbred C57BL
Th17 Cells*
Verteporfin / pharmacology

Substances

Verteporfin